Thermo Fisher Scientific Inc (NYSE:TMO, ETR:TN8) announced on Wednesday that it has agreed to acquire Clario Holdings Inc, a provider of endpoint data solutions for clinical trials, for nearly $8.9 billion in cash plus potential performance-driven payouts.
Thermo Fisher is purchasing the company from a shareholder group led by Astorg and Nordic Capital, Novo Holding and Cinven.
Clario is expected to generate revenue of about $1.25 billion in 2025, and Thermo Fisher expects the acquisition to be immediately accretive, adding $0.45 of adjusted earnings per share in the first year after the deal closes.
“Clario is an outstanding strategic fit, enabling faster, more informed drug development through differentiated technology and data intelligence solutions,” Thermo Fisher Scientific CEO Marc Casper said in a statement.
In addition to the initial cash purchase price at closing, Thermo Fisher has agreed to pay $125 million in January 2027.
The company will also pay up to $400 million of earn-out payments based on the performance of the business in 2026 and 2027.
Thermo Fisher Scientific shares rose 1.1% to $563.99 in late-morning trading on Wednesday.